共 16 条
[1]
New neuropathological criteria for Alzheimer disease. Hyman,BT. Archives of Neurology . 1998
[2]
An increased percentage of longamyloidβprotein secreted by familial amyloidβprotein precursor(βAPP717)mutants. Suzuki N,Cheung TT,Cai XD,et al. Science . 1994
[3]
Binding sites of{gamma}-secretaseinhibitors in rodent brain:distribution,postnatal development,and effectof deafferentation. Yan XX,Li T,Rominger MC,et al. The Journal of Neuroscience . 2004
[4]
Growth arrest of individualsenile plaques in a model of alzheimer’s disease observed by in vivo mul-tiphoton microscopy. Christie RH,Bacskai BJ,Zipfel WR,et al. The Journal of Neuroscience . 2001
[5]
Naturally secreted oligomersof amyloidβprotein potently inhibit hippocampal long-term potentiation invivo. Walsh DM,Klyubin I,Fadeeva JV,et al. Nature . 2002
[6]
Clogging of axons by tau,inhibition of axonal traffic and starving of synapses. Mandelkow EM,Stamer K,Vogel R,et al. Neurobiology of Aging . 2003
[7]
Secretases as targets for the treatment ofAlzheimer’s disease:the prospects. Dewachter I,Van Leuven F. The Lancet Neurology . 2002
[8]
Targeting small Aβoligomers:The solu-tion to an Alzheimer’s disease conundrum. Klein WL,Krafft G,Finch CE. Trends in Neurosciences . 2001
[9]
Therapeutically effective an-tibodies against amyloid-beta peptide target amyloid-beta residues 4-10and inhibit cytotoxicity and fibrillogenesis. McLaurin J,Cecal R,Kierstead ME,et al. Nature Medicine . 2002
[10]
Decreased prevalence ofalzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme areductase inhibitors. Wolozin B,Kellman W,Ruosseau P,et al. Archives of Neurology . 2000